论文部分内容阅读
AIM: To obtain an accurate evaluation of the association between high expression of epithelial cellular adhesion molecule(EpCAM) and gastric cancer(GC) risk.METHODS: Studies that had examined the association between high expression of EpCAM and GC risk were identified by searching electronic databases Pub Med, EMBASE, Cochrane library and Chinese Biomedical Literature database. Risk ratios(RRs) together with their 95%CIs were used to assess the association between high expression of EpCAM and GC risk. We selected eligible studies based on inclusion criteria. RevMan 5.3 software was used to calculate the pooled values.RESULTS: A total of 14 studies were included in this meta-analysis. EpC AM-positive cases were significantly associated with tumor size(RR: 1.68, 95%CI: 1.47-1.91, P < 0.00001 fixed-effect), depth of invasion(RR: 1.37, 95%CI: 1.11-1.68, P = 0.003 random-effect), TNM stage(RR: 2.02, 95%CI: 1.35-3.02, P = 0.0007 randomeffect), tumor location(RR: 0.80, 95%CI: 0.71-0.91, P = 0.0007 fixed-effect), histologic differentiation(RR: 1.23, 95%CI: 1.13-1.33, P < 0.00001 fixed-effect) and lymph node metastasis(RR: 1.89, 95%CI: 1.28-2.80, P = 0.001 random-effect). However, we did not observe any significant association between the presence of EpCAM with age, gender, distant metastasis, Borrmann type or Lauren classification. Additionally, EpCAM expression was not associated with the overall survival rate. The pooled HR of the overall effect was 1.39(95%CI: 0.30-6.48, P = 0.67 random-effect).CONCLUSION: Our meta-analysis indicates that EpCAM contributes to GC risk, which acts as a prognostic factor and a marker of poor outcome.
AIM: To obtain an accurate evaluation of the association between high expression of epithelial cellular adhesion molecule (EpCAM) and gastric cancer (GC) risk. METHODS: Studies that had examined the association between high expression of EpCAM and GC risk identified by searching electronic databases Pub Med, EMBASE, Cochrane library and Chinese Biomedical Literature database. Risk ratios (RRs) together with their 95% CIs were used to assess the association between high expression of EpCAM and GC risk. A total of 14 studies were included in this meta-analysis. EpC AM-positive cases were significantly associated with tumor size (RR: 1.68, 95% CI: 1.47-1.91, P <0.00001 fixed-effect, depth of invasion (RR: 1.37, 95% CI: 1.11-1.68, P = 0.003 random-effect), TNM stage (RR: 2.02, 95% CI: 1.35-3.02, ), tumor location (RR: 0.80, 95% CI: 0.71-0.91, P = 0 .0007 fixed-effect), histologic differentiation (RR: 1.23, 95% CI: 1.13-1.33, P <0.00001 fixed-effect) and lymph node metastasis (RR: 1.89, 95% CI: 1.28-2.80, -effect). However, we did not observe any significant association between the presence of EpCAM with age, gender, distant metastasis, Borrmann type or Lauren classification. Additionally, EpCAM expression was not associated with the overall survival rate. The pooled HR of the Overall effect was 1.39 (95% CI: 0.30-6.48, P = 0.67 random-effect). CONCLUSION: Our meta-analysis indicates that EpCAM contributes to GC risk, which acts as a prognostic factor and a marker of poor outcome.